Hormonal Resistance: Leptin and ghrelin, hormones that regulate hunger and fat storage , can become unbalanced, increasing cravings
I have more energy and zero side effects
So the same pharmaceutical company makes a pure insulin product (Toujeo), a combination insulin-plus-GLP-1 product (Soliqua), and markets them through similar channels to similar patient populations
Triple Agonist vs Dual Agonist Comparison Contents Key Takeaways Two Compounds, One Manufacturer, Different Receptor Counts Weight Loss: The Numbers Side by Side Mechanism Breakdown: What the Third Receptor Adds Safety: Where the Tradeoffs Appear Evidence Quality: Phase 2 vs Phase 3 Where Each Compound Might Win The Bottom Line Explore Research Peptides Retatrutide 12mg 24.2% body weight lost (Phase 2, 48 wk) vs Tirzepatide 15mg 22.5% body weight lost (Phase 3, 72 wk) 3 vs 2 receptor targets (retatrutide vs tirzepatide) 63% vs 57% reached 20%+ weight loss (highest dose arms) Eli Lilly same manufacturer for both compounds Sources: Retatrutide Phase 2 (NEJM, 2023), SURMOUNT-1 (NEJM, 2022)
As pharmacological studies highlight the hindbrain nucleus tractus solitarius (NTS) as a brain region important for GLP-1R-mediated effects on energy balance, AAV-GLP-1R was injected into the NTS to examine the role of endogenous NTS GLP-1R signaling in energy balance control
Providers are encouraged to exercise their own clinical judgment based on each individual patients health care needs.
